Epstein-Barr virus (EBV) glycoprotein 110 (gp110) has sequence homology with herpes simplex virus-1 (HSV-1) gB; however the role of gp110 in EBVs' life cycle differs from that of gB. Unlike HSV-1 gB, which is essential for HSV-1 infection but dispensable for virus production, gp110 is required for assembly and egress of EBV. EBV gp110 is found mainly in the endoplasmic reticulum (ER)/nuclear membrane, whereas little or no gp110 is detected in the plasma membrane or a mature viral particle. Conversely, HSV-1 gB is abundant in the envelope of mature virions and in the plasma membrane as well as in the ER/nuclear membrane of HSV-1-infected cells. Interestingly, there are four consecutive arginine residues (at positions 836-839 of gp110) in the C-terminal domain previously shown to be important for gp110's intracellular localization. To determine whether these arginines function as an ER/nuclear localization signal, point mutants were constructed differentially substituting the four arginines. The glycosylation pattern and intracellular localization of the mutants were investigated by assessing sensitivity to endoglycosidase H (endo H) digestion and performing indirect immunofluorescence assays. Substitution of part of the four arginines changed the glycosylation profile and targeting of gp110. In addition, mutations preserving the net charge of the four arginines as well as those causing net charge shift resulted in the changed intracellular localization and altered glycosylation pattern. These results suggest that not only the net charge but also the conformation of the four arginines are important for gp110's processing and subcellular localization.
INTRODUCTION
Epstein-Barr virus (EBV) glycoprotein 110 (gp110) is a 857-amino acid (aa) glycoprotein synthesized with a 22 aa cleavable signal sequence at the amino terminal. It consists of a 663 aa ectodomain containing nine potential N-linked glycosylation sites followed by three hydrophobic segments with a putative transmembrane domain and a 104 aa C-terminal tail (Pellett et al., 1985) . Previous studies have shown that gp110 is expressed during productive infection period but not during latency (Kishishita et al., 1984; Emini et al., 1987; Gong et al., 1987) . The function of gp110 has been investigated actively since the gene for gp110 was cloned and its sequence homology with herpes simplex virus-1 (HSV-1) gB was reported in 1987 (Gong et al., 1987) . The results obtained from lymphoblastoid cell lines (LCLs) infected with gp110-null mutant EBV demonstrated that gp110 is essential either for EBV entry or assembly but is dispensable for EBVdriven proliferation of latently infected transformed B lymphocytes (Herrold et al., 1996) . In concordance, a recent electron microscopy study implicated gp110 in EBV assembly and/or budding as neither nucleocapsids nor enveloped virions were observed in any cellular compartments of lytically activated LCLs harboring gp110-null mutant EBV . These results are interesting in comparison with the role of HSV-1 gB. HSV-1 gB, like EBV gp110, is also an essential gene in its own viral life cycle. However, gB functions exclusively during viral entry while dispensable in the process of production, assembly, and release of HSV-1 (Little et al., 1981; DeLuca et al., 1982; Cai et al., 1989) . In accordance with their different roles, gp110 and gB also differ structurally. The mature 110-kDa gp110 has endo H-sensitive, high mannose, N-linked oligosaccharides, indicating that gp110 does not traffic through Golgi membranes (Gong and Kieff, 1990) . This purely N-linked form is analogous to the immature form of HSV-1 gB but different from mature gB, which contains both N-and O-linked sugars (Wenske et al., 1982) . Little or no EBV gp110 is detected in the virion or the plasma membrane of infected cells but localizes predominantly in the inner and outer membranes of the nucleus and the endoplasmic reticulum (ER) (Gong and Kieff, 1990; Gong et al., 1987) . In contrast, HSV-1 gB protein is an abundant constituent of the virion envelope and found in ER/nuclear membrane as well as in the plasma membrane of infected cells (Ali et al., 1987) . The intracellular localization of gp110 and gB support their different roles. HSV-1 gB, required for viral entry to new host cells, is incorporated in the viral envelope through budding from the nuclear membrane of infected cells (Stannard et al., 1996) . On the other hand, gp110 plays an essential role in the process of viral assembly, which takes place in the nucleus where gp110 is abundantly expressed .
Previous reports have shown that the C-terminal domain, especially amino acids 817-841, of gp110 is important for intracellular localization of gp110 using truncation mutants and HSV-1 gB:EBV gp110 chimeric proteins . Contrary to this, it has been reported that both the N-and C-terminal domains of gp110 contain signals that are independently sufficient to direct gp110 to the ER/nuclear membrane (Papworth et al., 1997) . Presently, the mechanism for the ER/nuclear membrane localization of gp110 is not clearly understood. Many ER or nuclear resident proteins contain either ER retention signals or nuclear localization signals (NLSs) that are responsible for their proper targeting. If gp110 contained an ER retention signal, it would reach the nuclear envelope membrane by diffusion after it is made in the ER. However, gp110 does not contain the classical ER retention signal such as KDEL (Munro and Pelham, 1987; Pelham, 1990) . Most known NLSs have homology to the sequence PKKKRKV found in SV-40 large T antigen (Kalderon et al., 1984; Richardson et al., 1986; Burglin and De Robertis, 1987; Hauber et al., 1989; Cochrane et al., 1990) . Other nuclear proteins use the bipartite NLS usually consisting of two separate 3-4 consecutive positively charged amino acid residues (Antoine et al., 1997; Moore et al., 1998) . Thus many proteins utilize consecutively arranged positively charged amino acids for their nuclear targeting. Interestingly, four consecutive positively charged arginine residues are located in the C-terminal domain of gp110 at amino acids 836-839 within the sequences previously found to be important for gp110's intracellular localization , Papworth et al., 1997 . The four arginines may function as a NLS for gp110, causing its ER/nuclear membrane localization in infected cells.
The purpose of the present study is to determine whether the four consecutive arginine residues found in the C-terminal domain of gp110 are the only important sequences for its ER/nuclear localization. To clarify this, point mutations were introduced to the arginine sequences of gp110, and each mutant was assayed for its glycosylation pattern and intracellular localization.
RESULTS

Construction of gp110 point mutants
To investigate the importance of the four consecutive arginine residues at amino acids 836-839 for intracellular localization of gp110, four different point mutants with substitutions at all or part of amino acids 836-839 were constructed ( Fig. 1) . A gp110 expression vector pSVgp110 (Herrold et al., 1996) was used as a template to introduce point mutations using QuickChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA) by following the manufacturer's instructions. Positive charges of the wildtype RRRR sequence were preserved after the mutation in pSVgp110 (RKRR) and pSVgp110 (KKKK). In the other two point mutants, net charges were changed by amino acid substitution: the two positively charged arginines at position 837 and 838 were replaced with negatively charged glutamic acids in pSVgp110 (REER) or with neutral threonines in pSVgp110 (RTTR).
Expression of gp110 point mutants in BJAB cells
The expression pattern of each gp110 point mutant was studied in EBV-negative BJAB cells transfected with each expression construct. Following transfection the cells were radiolabelled and immunoprecipitated with the gp110-specific monoclonal antibody L2. Immunoprecipitated proteins were separated by SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis). Following electrophoresis, the gels were fixed and dried, and the immunoprecipitated proteins were visualized with autoradiography. As previously observed , the major protein immunoprecipitated with L2 from cells transfected with pSVgp110 corresponded in size with the glycosylated form of gp110 at 110 kDa (Fig. 2, lane 1) . From vector control (pSG5)-transfected cells, no immunoprecipitated protein was detected except nonspecific bands below the 66-kDa size marker (Fig. 2, lane 6) . The sizes of all four point mutants were expected to be the same as that of wild-type gp110. As expected, a protein band indistinguishable from wild-type gp110 was detected from cells transfected with each point mutant expression construct ( Fig. 2 , at 110 kDa position of lanes 2-5). However, a more slowly migrating diffuse protein band was detected in addition to 110-kDa gp110 in cells transfected with pSVgp110(KKKK), pSVgp110(REER), or pSVgp110(RTTR) (Fig. 2 , at 125 kDa position of lanes 3-5). These additional bands could represent differentially glycosylated gp110 due to a change in subcellular localization of the point mutants.
Glycosylation patterns of the point mutant gp110s
To test whether the slowly migrating protein immunoprecipitated with anti-gp110 monoclonal antibody as observed in Fig. 2 is gp110 with a changed glycosylation pattern, the mutant gp110s were treated with endo H following immunoprecipitation. As endo H specifically cleaves high-mannose N-linked oligosaccharides but not complex oligosaccharides, the resistance to endo H treatment indicates that a glycoprotein is modified with complex sugars by processing through the Golgi apparatus. All carbohydrates were removed from wild-type gp110 using endo H, which resulted in a decrease of molecular mass to 93 kDa (Fig. 3 . lane 2 vs lane 1), corresponding to the unmodified form of gp110 predicted from its amino acid composition (Gong et al., 1987) . These data confirmed results obtained by other investigators (Gong and Kieff, 1990; Papworth et al., 1997) , demonstrating that wild-type gp110 possesses mainly high-mannose-type glycosylation and that it is not further modified by Golgi enzymes. A slight difference in migration of the endo-H-treated gp110 and gp110 produced from tunicamycin treated cells was noticeable (Fig. 3,  lane 2 vs lane 3) . The difference would be due to the fact that endo H leaves the N-acetylglucosamine linker at asparagine residues after digestion, while tunicamycin blocks the first step of glycosylation, causing no sugar addition on gp110 (Tarentino et al., 1974) . Immunoprecipitated gp110(RKRR) showed not only the same mobility but also the same deglycosylation pattern with endo H treatment as wild-type gp110 (Fig. 3 , lanes 4 and 5 compared with lanes 1 and 2). These results suggest that substituting arginine at position 837 with lysine did not disturb the subcellular localization of gp110. On other hand, the results obtained from cells transfected with pSVgp110(KKKK), pSVgp110(REER), and pSVgp110(RTTR) For the glycosylation analysis, the BJAB cells were transfected with the indicated plasmids and labeled with [ 35 S] with or without tunicamycin treatment. Twenty-four hours after transfection, the cells were harvested and subjected for immunoprecipitation as described in Fig. 2 . Parts of the immunoprecipitated proteins were eluted and digested with endo H. Endo-H-(E) and mock-treated (U) samples were then separated together with tunicamycin treated (T) samples by SDS-PAGE for further analysis as described in Fig. 2 . Immunoprecipitated proteins from equivalent cell numbers were loaded in lanes for mock-and endo-H-treated samples while the proteins from approximately onethird of the cell numbers were loaded for tunicamycin treated samples for SDS-PAGE. Molecular weight standards are indicated at the left in kilodaltons. The locations of the slowly migrating 125-kDa, partially deglycosylated 105 -kDa, and the nascent 93-kDa gp110 as well as the 110-kDa wild-type gp110 are indicated at the right. were similar to one another but different from those obtained from cells transfected with the wild-type gp110 expression vector. As shown in Fig. 2 , two distinct proteins migrating with different mobility were visualized in the untreated cells (Figs. 2, lanes 3-5, and 3, lanes 7, 10, and 13). The protein migrating at the same position as wild-type gp110 was reduced in size to ϳ93 kDa with endo H treatment (Fig. 3, lanes 8, 11, and 14 at 93 kDa); the reduction in size is evidence of its high mannose content and lack of complex sugars. Contrary to this result, the band migrating slower than wild-type gp110 (125 kDa) underwent a small mobility shift with endo H digestion. This indicates that part of the mutant proteins were transported from the ER to Golgi and further modified with complex sugars (Fig. 3, lanes 8, 11, and 14 at 105 kDa).
Intracellular localization of the gp110 point mutant proteins in B cells
To confirm that the changed glycosylation pattern and mobility on SDS-PAGE of the three point mutants, pSVgp110(KKKK), pSVgp110(REER), and pSVgp110(RTTR), were due to disturbed ER/nuclear membrane retention of gp110, the intracellular localization of the point mutants was studied in a B cell line. At 24 h after transfection with each expression vector, BJAB cells were subjected to indirect immunofluorescence assays. No reactivity was observed in vector control transfected cells with the L2 antibody (Fig. 4, pSG5 ). As previously reported , wild type gp110 was detected in fixed but not in live cell preparations using monoclonal antibody L2 indicating that gp110 was retained to the ER and nuclear membrane (Fig. 4, gp110) . Likewise, gp110(RKRR) was detected in fixed but not live cell preparations showing that arginine to lysine substitution at position 837 did not disturb the ER/nuclear membrane localization pattern of gp110 (Fig. 4) . In contrast, gp110(KKKK), gp110(REER), and gp110(RTTR) were easily observed in both the live and fixed cell preparations, implying that at least part of these gp110 mutants were expressed on the plasma membrane of the transfected cells (Fig. 4) . Thus the substitutions made in these three mutants affected gp110's subcellular localization pattern in B cells, supporting the role of the four arginine residues in gp110's intracellular localization. 
Intracellular localization of the gp110 point mutant proteins in epithelial cells
EBV infection of epithelial cells is detected in pathological conditions such as nasopharyngeal carcinoma and oral hairy leukoplakia as well as the ordinary infection cycle (Sixbey et al., 1984; De Souza et al., 1989; Weiss et al., 1989; Niedobitek et al., 1991) . Thus to test whether the four arginines in the C-terminal domain of gp110 function as a nuclear/ER targeting signal in epithelial cells as well as in B cells, immunofluorescence studies were performed. Two different epithelial cell lines HeLa and SiHa were grown on 10-well slides. Cells were transfected with each expression vector using Lipofectamine reagent. Twenty-four hours posttransfection, cells were fixed and subjected to indirect immunofluorescence. Identical results were obtained from HeLa and SiHa cells and the results from HeLa cells are shown on Fig. 5 . No reactivity was observed in vector control transfected cells with L2 antibody (Fig. 5, pSG5) . In cells transfected with wild-type gp110 or gp110(RKRR), the staining pattern with L2 was rather small and round confined to the nuclear membrane with some staining of intracellular membranes consistent with ER/nuclear membrane localization (Fig. 5) . In contrast, the staining pattern with L2 was larger and irregular matching with the HeLa cell's elongated shape with pointed ends in cells transfected with gp110(KKKK), gp110(REER), or gp110(RTTR) mutants (Fig. 5) . These results show that the subcellular localization of wild-type gp110 and mutant gp110s in epithelial cells does not differ from that in B cells.
DISCUSSION
Previous efforts to clarify sequences of gp110 important for its ER/nuclear membrane localization have shown disparate results. Some results imply that only the C-terminal domain of gp110 is important , whereas others suggest that both the N-and C-terminal domains can target gp110 to ER/nuclear membrane independently to each other (Papworth et al., 1997) . In the C-terminal domain, which was shown to play a role in gp110's subcellular localization by all the previous results, four consecutive arginine residues are found. Short stretches of positively charged amino acids have been shown to function as NLS for various proteins (Kalderon et al., 1984; Richardson et al., 1986; Burglin and De Robertis, 1987; Hauber et al., 1989; Cochrane et al., 1990; Antoine et al., 1997; Moore et al., 1998) . The purpose of this study was to investigate whether the four consecutive arginine residues found in the C-terminal domain of gp110 function as NLS for gp110.
Roughly half of the gp110(KKKK), gp110(REER), and gp110(RTTR) was detected at 125 kDa, whereas the remaining half was detected at 110 kDa on SDS-PAGE. The 125 kDa form of gp110 was partially resistant to endo H digestion unlike the 110-kDa gp110, which was completely digested to produce 93-kDa nascent gp110 (Gong and Kieff, 1990) . This is unlikely to be a result of incomplete endo H digestion because the 110-kDa form of gp110 was completely digested under the same conditions. Rather, the appearance of a more slowly migrating 125-kDa band of mutant gp110s is explained by acquisition of complex sugars in the Golgi apparatus. As expected, these mutant gp110s were detected in the plasma membrane. These three gp110 mutants are very similar to HSV-1 gB and human cytomegalovirus (HCMV) gB in regard to their glycosylation pattern and intercellular localization. Studies on HSV-1 gB and HCMV gB indicated that two distinct forms of wild-type gBs are found in cells infected with these viruses. One form is modified with complex oligosaccharides, which are only partially sensitive to endo H digestion, whereas the other form is glycosylated with endo-H-sensitive high mannose oligosaccharides (Britt and Vugler, 1989; Radsak et al., 1990; Navarro et al., 1991 Navarro et al., , 1993 . These results suggest that a proper structural configuration as well as the positive charge of the four arginine residues are required for retention of gp110 in ER/nuclear membrane as the net charge of gp110(KKKK) is conserved after mutation.
The RKRR sequence introduced in the gp110(RKRR) mutation is found in HSV-1 gB at the corresponding location to RRRR of EBV gp110 (Pellet et al., 1985; . HSV-1 gB is modified at a post-ER compartment and localizes in the plasma membrane as well as in the ER/nuclear membrane of infected cells (Wenske et al., 1982; Ali et al., 1987) . The mutant gp110(RKRR) was indistinguishable from wild-type gp110 in terms of its endo H sensitivity and intracellular localization as well as its mobility on SDS-PAGE. This indistinguishable mutant gp110 correlates with the results, showing that the NLS of HSV-1 gB is not present on its C-terminal domain containing this RKRR sequence but found in the hydrophobic domain from amino acids 774-795 (Gilbert et al., 1994) . In HSV-1 gB, the RKRR sequence is present but other structural requirements for that sequence to function must not be present to explain the different intracellular localization of HSV-1 gB compared to EBV gp110. The results obtained from gp110(RKRR) together with the results from the other three point mutant gp110s suggest that although the four arginine residues are important for gp110's intracellular localization, some other structural or configurational properties around this NLS may influence the protein's targeting. Further study is required to investigate the characteristics of gp110 important for its unique localization.
In summary, the results obtained from the present study indicate that mutation of the four arginines at amino acids 836-839 within the C-terminal tail domain of gp110 is sufficient to change the intracellular transport and localization of gp110. Similar in gp110, consecutively arranged arginines/lysines function as nuclear localization signals in several viral proteins including human immunodeficiency virus tat and rev (Hauber et al., 1989; Cochrane et al., 1990) , murine cytomegalovirus M44 gene product pp50 (Loh et al., 1999) , and EBV nuclear antigen 2 (Cohen et al., 1991) . As mentioned already, Papworth et al. (1997) identified sequences important for nuclear membrane localization and ER retention in the Nand C-terminal portion of gp110. In that study, gp110 truncation and chimeric proteins were expressed in a rabbit kidney epithelial cell line, RK13, infected with recombinant vaccinina virus. The results presented in the current study indicate that the N-terminal domain alone does not function as NLS for gp110 in B cells and some epithelial cell lines. The differences observed in the two studies might be due to the absence of a specific cellular factor present in the RK13 cells. Furthermore drastic structural change can cause misfolding of the protein resulting in erroneous protein transport. Thus the results obtained from deletion mutants and chimeric proteins should be interpreted with caution.
The current study indicates the four arginines contained within the gp110 C-terminal tail may interact with specific unknown cellular proteins to ensure retention of gp110 within the nuclear membrane and ER. Further experiments examining which cellular proteins interact with the C-terminal domain of gp110 and elucidation of the 3-dimensional structure of gp110 will delineate how the four arginines of gp110 function as a nuclear membrane targeting signal.
MATERIALS AND METHODS
Cell lines and cell culture
BJAB is an EBV-negative B-lymphoma cell line (Menezes et al., 1975) . BJAB cells were maintained in RPMI serum, 1000 U of penicillin/ml, and 1000 mg of streptomycin (Sigma Chemical Co., St. Louis, MO) per milliliter. HeLa and SiHa are epithelial cell lines (Heiles et al., 1988) . They were maintained in DMEM medium containing 10% inactivated fetal bovine serum, 1000 U of penicillin/ml, and 1000 mg of streptomycin (Sigma Chemical Co., St. Louis, MO) per milliliter.
Construction of plasmids
A gp110 expression vector pSVgp110 (Herrold et al., 1996) was used as a template to introduce point mutations using QuickChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA) by following the manufacturer's instruction. The oligonucleotide sequences designed to introduce point mutations are shown below with the nucleotide sequences for R-836-R-837-R-838-R-839 underlined and with the substituted sequences in lowercase letters: 5Ј-CCAGGCCTACGCAaAAGACGCTATCAC-GATCC-3Ј changed codon R-836 to K in pSVgp110(RKRR); 5Ј-CGTTTTCCAGGCCTAaagAaAAaAaagTATCACGATCC-3Ј changed codon R-836-R-837-R-838-R-839 to KKKK in pSVgp110(KKKK); 5Ј-CCAGGCCTACGCgaAgaACGCTATCA-CGATCC-3Ј changed codon R-837-R-838 to EE in pSVgp110(REER); and 5Ј-CCAGGCCTACGCAcAAcACGC-TATCACGATCC-3Ј changed codon R-837-R-838 to TT in pSVgp110(RTTR). After mutagenesis the clones were sequenced by the dideoxy-chain termination method to confirm the authenticity (data not shown).
Transfections
Transfections into BJAB cells were performed by electroporation as previously described . Briefly, 10 7 cells were resuspended in 400 l RPMI 1640 containing 10 g of each plasmid and electroporated using a Gene Pulser electroporator (Bio-Rad Lab. Hercules, CA). Cells then were transferred to 25-cm 2 flasks containing complete RPMI 1640 medium and incubated at 37°C in a 5% CO 2 incubator.
Transfection into HeLa and SiHa cell lines were performed as previously reported with slight modification . Briefly, subconfluent epithelial cells grown on 10-well glass slides were overlaid with purified plasmid DNA and Lipofectamine Reagent (Gibco BRL, Gaithersburg, MD) mixture in Opti-MEM (Gibco BRL, Gaithersburg, MD). Following 5-h incubation at 37°C after transfection, the mixture was removed and complete DMEM medium was added for further culture.
Immunoprecipitation of radiolabeled cells
The expression pattern of each gp110 point mutant was studied in EBV negative BJAB cells transfected with each expression vector . After transfection, cells were radiolabelled with [ 35 S]methionine. Twenty-fours hour later, cells were washed with phosphate-buffered saline (PBS) and lysed in 1% N-P40 lysis buffer [1% Nonidet-P40, 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 2 mM EDTA, 1 g each pepstatin and leupeptin per ml, 0.5 mM phenylmethylsulfonyl fluoride, 1 mM sodium orthovanadate]. The insoluble material was removed by centrifugation at 4°C. Cleared lysates were immunoprecipitated with monoclonal antibody against gp110 (L2, Chemicon, Temecula, CA) for 1 h at 4°C and captured with protein G-Sepharose. Samples were then washed four times in 1% N-P40 lysis buffer, mixed with equal volumes of 2ϫ sodium dodecyl sulfate (SDS) sample buffer, incubated at 95°C for 1 min, and separated by SDS-8% polyacrylamide gel electrophoresis (PAGE). Gels were fixed, dried, and subjected to autoradiography.
Glycosylation pattern analysis of the point mutant gp110s
For the glycosylation analysis of each gp110 point mutant, the BJAB cells were transfected with the indicated plasmids and divided into two parts for control and tunicamycin treatment. Twenty micrograms per milliliter tunicamycin (Boehringer Mannheim, Mannheim, Germany) was added to block glycosylation of proteins while vehicle (dimetylformamide) was added for control experiments at 1 h posttransfection. [ 35 S]methionine (500 Ci/ ml) was added to the media 1 h after tunicamycin/vehicle treatment for labeling. Twenty-four hours after transfection, the cells were harvested and subjected for immunoprecipitation. The immunoprecipitated proteins from the tunicamycin treated cells were kept frozen at Ϫ70°C until SDS-PAGE analysis. The immunoprecipitated proteins from the control cells were eluted and divided into two aliquots for endo H (Boehringer Mannheim, Mannheim, Germany) or mock digestion. Each aliquot was incubated for 16 h with 5 mU endo H/sample or water (for mock digestion) at 30°C. Endo H and mock treated samples were then separated together with tunicamycin treated samples by SDS-PAGE for further analysis.
Immunofluorescence studies BJAB cells were subjected for immunofluorescence studies 24 h after transfection with each expression vector as previously described . For the fixed-cell immunofluorescence, the cells were dried on glass slides, fixed with acetone at Ϫ20°C for 5 min, blocked with 20% normal goat serum for 10 min at room temperature, and incubated with anti-EBV gp110 monoclonal antibody diluted 1:1000 for 1 h. The cells were then incubated with an anti-mouse fluorescein isothiocyanate (FITC) secondary antibody diluted 1:1000 and viewed with a fluorescence microscope. For the live-cell immunofluorescence, 1 ml of BJAB cell suspension was pelleted in a tube and resuspended in 20% normal goat serum containing anti-gp110 monoclonal antibody diluted 1:1000. Following incubation on ice for 1 h with gentle agitation, the cells were washed twice, dried on glass slides, incubated with an anti-mouse FITC secondary antibody, and viewed.
For epithelial cells, only fixed cells were used for immunofluorescence studies. HeLa or SiHa cells were cultured for 24 h after transfection before used in immunofluorescence studies. Cells were washed once with PBS, dried on a 37°C heating block, then fixed, blocked, and treated with antibodies for visualization as described above.
